



Short version of press release from Emotra AB  
Gothenburg August 27, 2013

## The Swedish-German study accepted for publication

- *In clinical studies a strong relationship between hyporeactivity and risk for suicide has been demonstrated*
- *Emotra has developed, EDOR, ElektroDermal Orientation Reactivity, and objective and quantitative psychophysiological test for the measurement of hyporeactivity*
- *Evaluation of suicide risk is the most challenging problem for the psychiatric care to solve*

---

The article, which reports on the results from the Swedish- German study, has now been accepted for publication in the prestigious international scientific *"Journal of Psychiatric Research"*. In the study, test results from 783 German patients have been analyzed with Emotra's (Lars-Håkan Theorell's) accurate methods. All previous results about the strong relationship between hyporeactivity and suicide risk have been confirmed.

The German teams, involved in the study are all leading research groups within the German and international suicide research. One of the co-authors, is Manfred Wolfersdorf, Professor in psychiatry in Bayreuth. Two other co-authors are Wolfgang Kaschka, Professor in psychiatry and the well-recognized psychologist, Roland Straub, in Ravensburg. They are all leading scientists within the field of suicide prevention and electrodermal reactivity.

The fact that this important scientific work has been accepted for publication will contribute to get acceptance for EDOR from the psychiatric specialists in Germany and other countries. Professor Kaschka will present the results from the study at a large international congress in Lisbon in September 2013. At the moment, EDOR, is met by an increased international recognition.

The psychiatric care has relevant preventive actions and resources to use when risk for suicide has been identified. Unfortunately there are today no accurate methods for the identification of risk patients, with the use of EDOR this difficult diagnostic problem can be solved. The test does not take more than 15 minutes. With necessary preparations, the total time is 30 minutes. The introduction of EDOR as a clinical routine procedure has the potential to substantially reduce the number of suicides and suicide attempts in the world.

*For more information, please contact*

*Claes Holmberg, President and CEO, Emotra AB, Telephone: +46708254547, [claes@emotra.se](mailto:claes@emotra.se)*

*or Lars-Håkan Thorell, Research Manager, Emotra AB, Telephone: +46703263853, [lars@emotra.se](mailto:lars@emotra.se)*

---

**Emotra AB** is a Swedish medical device company focusing on research, development, clinical trials and marketing within the field of suicide prevention. The company's method, EDOR, is an objective and quantitative diagnostic psychophysiological test of hyporeactivity. During the test, the patients listen and react to a series of sound signals. The response is measured as minimal fluctuations in the dermal electrical conductivity and analyzed. With research and clinical documentation an extremely sensitive and accurate test, with the purpose of evaluating suicide risk, has been developed.

Emotra AB, Göteborgsvägen 74, 433 63 Sävedalen, Sweden

Telephone: +46 708 25 45 47, [www.emotra.se](http://www.emotra.se)